Amedisys (AMED) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investors ...

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companie ...

BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, has 92 home health and hospice care centers recognized by Strategic Healthcare Programs (SHP) for achieving the highest overall HHCAHPS patient satisfaction or CAHPS Hospice caregiver satisfaction scores of all eligible SHP clients in 2023. This includes 14 care centers awarded Premier Performer, ranking in the top 5%, and 78 care centers awarded Su ...

NASHVILLE, Tenn., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today, Contessa Health, a subsidiary of Amedisys Inc. (Nasdaq: AMED), announced they have been selected by the Centers for Medicare & Medicaid Services (CMS) to participate in a new Medicare alternative payment model designed to support people living with dementia and their caregivers. Under CMS’ Guiding an Improved Dementia Experience (GUIDE) Model, Contessa will be one of almost 400 participants building Dementia Care Programs (DCPs) across the country, ...

Amedisys, Inc. (AMED) reported adjusted earnings per share (EPS) of $1.32 in the second quarter of 2024, down 3.6% year over year. However, the metric beat the Zacks Consensus Estimate by 8.2%.The quarter’s adjustments include certain merger-related expenses and other (income)/expenses, net.GAAP EPS in the second quarter was 98 cents compared to a loss of $2.46 in the same period last year.Net service revenues totaled $591.2 million, up 6.9% year over year. The top line surpassed the Zacks Consensus Estimat ...

Amedisys (AMED) reported $591.19 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 6.9%. EPS of $1.32 for the same period compares to $1.37 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $579.34 million, representing a surprise of +2.05%. The company delivered an EPS surprise of +8.20%, with the consensus EPS estimate being $1.22.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AMED The NASDAQ Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR ...

Amedisys (AMED) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.20%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.01 per share when it actually produced earnings of $1.03, delivering a surprise of 1.98%.Over the la ...

Exhibit 99.1 AMEDISYS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS BATON ROUGE, Louisiana (July 24, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 • Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023. • Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ...

BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable ...